



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/611,649	07/01/2003	Chris Rundfeldt	HUBR-1221	2085
24972	7590	07/22/2009	EXAMINER	
FULBRIGHT & JAWORSKI, LLP			KANTAMneni, SHOBHA	
666 FIFTH AVE			ART UNIT	PAPER NUMBER
NEW YORK, NY 10103-3198			1617	
MAIL DATE		DELIVERY MODE		
07/22/2009		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief	Application No.	Applicant(s)
	10/611,649	RUNDFELDT ET AL.
	Examiner	Art Unit
	Shobha Kantamneni	1617

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 25 June 2009 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1. The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

a) The period for reply expires 4 months from the mailing date of the final rejection.
 b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

NOTICE OF APPEAL

2. The Notice of Appeal was filed on _____. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

AMENDMENTS

3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
 (a) They raise new issues that would require further consideration and/or search (see NOTE below);
 (b) They raise the issue of new matter (see NOTE below);
 (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
 (d) They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: _____. (See 37 CFR 1.116 and 41.33(a)).

4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).

5. Applicant's reply has overcome the following rejection(s): _____.

6. Newly proposed or amended claim(s) _____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

7. For purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: NONE.

Claim(s) objected to: _____.

Claim(s) rejected: 1-4,6,8-13,15,17,18 and 20-23.

Claim(s) withdrawn from consideration: _____.

AFFIDAVIT OR OTHER EVIDENCE

8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

REQUEST FOR RECONSIDERATION/OTHER

11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: see page 2.

12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s). _____

13. Other: _____.

/SCREENI PADMANABHAN/
Supervisory Patent Examiner, Art Unit 1617

3. Applicant's proposed amendment which amended claim 20 herein, by changing limitations and the scope of claim, present a new issue for search and consideration by the Examiner. Therefore, the proposed amendment After Final will not be entered. Note that applicant's amendment, if entered would overcome the 112, second paragraph rejection.

11 . All rejections of record in the Final Office Action dated 02/26/2009 are MAINTAINED, as discussed in the final office action, and those found below.

Applicant argues that "Furthermore, other PDE4 inhibitors besides cilomilast are not effective for the treatment of allergic skin diseases if these are solely administered after the allergic challenge." These arguments have been considered, but not found persuasive. Contrary to applicant's remarks that other PDE4 are not effective for the treatment of allergic skin disease if these are solely administered after the allergic challenge, Hanifin discloses a method of treatment of atopic dermatitis comprising topical administration of PDE4 inhibitor CP80,633 ointment to patients with atopic dermatitis to treat inflammation i.e application solely after an allergic challenge is taught. Hanifin teaches significant reduction in the inflammation. See Hanifin et al., The Journal of Investigative Dermatology, Vol.107, No.1, July 1996, pages 51-56; abstract; page 52, left hand colum; page 52, right hand column under Topical Therapy.

As discussed, in the previous office actions, it would have been obvious to a person of ordinary skill in the art at the time of invention to administer (N-3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1H- indol-3yl]-2-oxoacetamide for the first time after an allergic challenge with reasonable expectation of treating atopic dermatitis because 1) according to Baumer et al. or Hofgen et al. (N-3,5- dichloro-4-pyridinyl)-2-[1 -(4-fluorobenzyl)-5-hydroxy- 1 H-i ndol-3yl]-2-oxoacetamide is known to treat allergic skin diseases such as allergic dermatitis, and further 2) the optimization of result effect parameters e.g., dosage range, dosing regimens, dosing duration is obvious as being within the skill of the artisan, involving merely routine skill in pharmaceutical art. Further, as discussed above PDE4 inhibitor CP80,633 treats atopic dermatitis/allergic dermatitis when applied topically to skin inflammation.